Valentin del Rio Santiago, MD
Interventional Cardiology · Manati, PRNPI 1790982155
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,500 of the $27,709 with a category attached, or 74.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 81.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $8,900 and has fallen 91.6% since, to $747 in 2025.
Across 191 payments — averaging $145.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
- Medtronic$3K
- Boston Scientific$1K
- AstraZeneca$259
- Teleflex LLC$230
- Abbott$137
- plus $470 from 9 others
What the payments were for
- Speaking & faculty fees$20,50074%
- Food & beverage$7,20926%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 81 | $22,490 |
| Medtronic(2 entities) | 57 | $2,895 |
| Boston Scientific | 26 | $1,228 |
| AstraZeneca | 9 | $259 |
| Teleflex LLC | 3 | $230 |
| Abbott | 2 | $137 |
| Biotronik Inc. | 2 | $124 |
| E.r. Squibb & Sons, L.L.C. | 2 | $117 |
| Terumo Medical Corporation | 1 | $67 |
| Boehringer Ingelheim | 2 | $43 |
| Cordis US CORP. | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Inari Medical, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$20,800
- Resolute$340
- Micra$249
- ONYX FRONTIER$187
- MEDTRONIC REUSABLE INSTRUMENTS$150
- CROSSBOSS$137
- CoreValve Evolut$132
- WATCHMAN Access System$130
- FARXIGA$127
- CLARIA MRI QUAD CRT-D SURESCAN$121
- General - CT_IC$120
- ARCTIC FRONT ADVANCE$116
- Amplia MRI$115
- Watchman$113
- RESOLUTE ONYX$109
- Xience Sierra Coronary Stent System$102
- ANGIOJET$101
How this compares
$27,709 in reported general payments places this provider in the 65th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $385,485 |
| XareltoRivaroxaban | 92 | $87,460 |
| FarxigaDapagliflozin Propanediol | 82 | $84,319 |
| BrilintaTicagrelor | 98 | $79,764 |
| EntrestoSacubitril/Valsartan | 33 | $35,287 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 173 | $32,352 |
| JardianceEmpagliflozin | 31 | $29,931 |
| Candesartan Cilexetil | 128 | $17,923 |
| Repatha SureclickEvolocumab | 26 | $16,913 |
| Metoprolol Succinate | 886 | $15,606 |
| Atorvastatin Calcium | 1,143 | $15,536 |
| Losartan Potassium | 1,016 | $13,836 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 410 | $9,947 |
| ClopidogrelClopidogrel Bisulfate | 635 | $8,748 |
| Carvedilol | 749 | $8,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $259 | $164,083180 claims |
| Johnson & JohnsonXarelto | $23 | $87,46092 claims |
| Boehringer IngelheimJardiance | $43 | $29,93131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Manati
- Ricardo SantiagoManati$131K
- Julio Valentin NievesManati$32K
- Nelson Espinell GonzalezManati$9K
- Abner Nieves TorresManati$8K
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Alejandro Lopez MasPonce$142K
- Edwin I Perez MarreroSan Juan$129K
- Pedro Colon HernandezCaguas$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.